SG11201607627RA - Compositions and methods for preventing or treating chronic lung allograft dysfunction and idiopathic pulmonary fibrosis - Google Patents

Compositions and methods for preventing or treating chronic lung allograft dysfunction and idiopathic pulmonary fibrosis

Info

Publication number
SG11201607627RA
SG11201607627RA SG11201607627RA SG11201607627RA SG11201607627RA SG 11201607627R A SG11201607627R A SG 11201607627RA SG 11201607627R A SG11201607627R A SG 11201607627RA SG 11201607627R A SG11201607627R A SG 11201607627RA SG 11201607627R A SG11201607627R A SG 11201607627RA
Authority
SG
Singapore
Prior art keywords
compositions
preventing
methods
pulmonary fibrosis
idiopathic pulmonary
Prior art date
Application number
SG11201607627RA
Other languages
English (en)
Inventor
Colleen Brophy
Cynthia Lander
Paul W Noble
Original Assignee
Moerae Matrix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Moerae Matrix Inc filed Critical Moerae Matrix Inc
Publication of SG11201607627RA publication Critical patent/SG11201607627RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
SG11201607627RA 2014-03-14 2015-03-12 Compositions and methods for preventing or treating chronic lung allograft dysfunction and idiopathic pulmonary fibrosis SG11201607627RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461953438P 2014-03-14 2014-03-14
PCT/US2015/020263 WO2015138784A2 (en) 2014-03-14 2015-03-12 Compositions and methods for preventing or treating chronic lung allograft dysfunction (clad) and idiopathic pulmonary fibrosis (ipf)

Publications (1)

Publication Number Publication Date
SG11201607627RA true SG11201607627RA (en) 2016-10-28

Family

ID=54067793

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201607627RA SG11201607627RA (en) 2014-03-14 2015-03-12 Compositions and methods for preventing or treating chronic lung allograft dysfunction and idiopathic pulmonary fibrosis

Country Status (12)

Country Link
US (1) US20150258192A1 (ko)
EP (1) EP3116543A4 (ko)
JP (1) JP6655547B2 (ko)
KR (1) KR20160124236A (ko)
CN (1) CN106456758A (ko)
AU (1) AU2015229251A1 (ko)
BR (1) BR112016021000A2 (ko)
CA (1) CA2942517A1 (ko)
MX (1) MX2016011852A (ko)
RU (1) RU2016140332A (ko)
SG (1) SG11201607627RA (ko)
WO (1) WO2015138784A2 (ko)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3352792B1 (en) * 2015-09-25 2020-08-26 Cedars-Sinai Medical Center Targeting fibroblast invasion for pulmonary fibrosis
WO2019070908A1 (en) 2017-10-03 2019-04-11 Cedars-Sinai Medical Center METHODS OF TARGETING THE PD1 PATHWAY OF THE IMMUNE CONTROL POINT FOR THE TREATMENT OF PULMONARY FIBROSIS
AU2019448236B9 (en) * 2019-05-30 2024-07-11 National Institute Of Biological Sciences, Beijing Animal model of idiopathic pulmonary fibrosis, its construction method and use
EP4185382A1 (en) * 2020-07-24 2023-05-31 Bristol-Myers Squibb Company Methods of treating acute respiratory disorders
CN112575074B (zh) * 2020-10-09 2022-12-27 中山大学 Nestin基因及蛋白在治疗器官纤维化中的应用
WO2022147172A1 (en) * 2020-12-30 2022-07-07 Briotech, Inc. Methods and compositions of aqueous hypobromous acid for the treatment and prevention of inflammatory conditions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070280930A1 (en) * 2004-03-17 2007-12-06 Kasper Mathias Antoon Rouschop Cd44-Targeting for Reducing/Preventing Ischemia-Reperfusion-Injury
US7723336B2 (en) * 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US20080199426A1 (en) * 2007-01-11 2008-08-21 Sukhatme Vikas P Methods and compositions for the treatment and diagnosis of vascular inflammatory disorders or endothelial cell disorders
DK2696888T3 (en) * 2011-04-12 2019-03-25 Moerae Matrix Inc COMPOSITIONS AND METHODS FOR PREVENTION OR TREATMENT OF PULMONAL FIBROSE
US10232039B2 (en) * 2011-04-12 2019-03-19 Duke University Compositions and methods for the treatment of tissue fibrosis

Also Published As

Publication number Publication date
WO2015138784A3 (en) 2015-10-29
KR20160124236A (ko) 2016-10-26
RU2016140332A3 (ko) 2018-10-11
RU2016140332A (ru) 2018-04-16
WO2015138784A2 (en) 2015-09-17
CN106456758A (zh) 2017-02-22
US20150258192A1 (en) 2015-09-17
EP3116543A2 (en) 2017-01-18
CA2942517A1 (en) 2015-09-17
EP3116543A4 (en) 2017-09-06
BR112016021000A2 (pt) 2017-10-03
JP6655547B2 (ja) 2020-02-26
AU2015229251A1 (en) 2016-09-22
MX2016011852A (es) 2017-05-09
JP2017509633A (ja) 2017-04-06

Similar Documents

Publication Publication Date Title
PT3496739T (pt) Composições compreendendo polipéptidos actriia para uso no tratamento de hipertensão pulmonar
HK1249028A1 (zh) 自發泡組合物和方法
HK1252454A1 (zh) 清潔組合物
GB2546350B (en) Compositions and methods
IL246383A0 (en) Polyoxometalate and heteropolyoxometalate preparations and methods of using them
KR101830290B9 (ko) 지방 유래 줄기세포로부터 추출된 엑소좀을 유효성분으로 포함하는 폐 섬유증 예방 또는 치료용 조성물
GB201718876D0 (en) Antithrombin-heparin compositions and methods
SG11201607627RA (en) Compositions and methods for preventing or treating chronic lung allograft dysfunction and idiopathic pulmonary fibrosis
GB201417828D0 (en) New methods and compositions
SG11201608128UA (en) Polishing composition and polishing method
PL3256589T3 (pl) Kompozycje i sposoby kontrolowania leptinotarsa
IL287983A (en) 15-hepe or a preparation containing 15-hepe for the treatment or prevention of fibrosis
ZA201800219B (en) Cleaning composition
PT3510167T (pt) Métodos e composições para prever disfunção crónica de aloenxerto pulmonar
HK1244692A1 (zh) 治療纖維化的方法
ZA201700413B (en) Flavor barrier composition
HUE050456T2 (hu) Dimetil-amino-mikeliolid tüdõfibrózis kezelésében történõ alkalmazásra
ZA201802419B (en) Hard surface cleaning composition
HK1244448A1 (zh) 用於治療肺高血壓的方法
ZA201901099B (en) Compositions for the treatment of pulmonary fibrosis
PT3645735T (pt) Métodos e composições para prever disfunção crónica de aloenxerto pulmonar
EP3610018A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF PULMONARY FIBROSIS
EP3285794A4 (en) METHODS FOR THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
EP3389715A4 (en) COMPOSITIONS AND METHODS FOR TREATING CARDIAL DYSFUNCTION
EP3139912A4 (en) Method of treating idiopathic pulmonary fibrosis